| A Cancer Immunotherapy Company |
Our technology is based on experimental discovery showing that B-lymphocytes, which produce antibodies against pathogens, develop an aggressive behavior in response to the presence of a tumor cell. In the course of adenocarcinoma cancer development, B-lymphocytes become polarized into making antibodies against certain types of tumor-associated antigens. These antibodies, however, do not effectively kill tumor cells. Instead they sustain a chronic inflammatory process that facilitates both tumor invasion and metastasis. BioCrystal refers to this process as a “pro-tumor immune response.” This discovery was first published in Neoplasia in 1999, and in Cancer Immunology and Immunotherapy in 2000. |
| |
| Cancer treatment regimens are beginning to address the tumor concomitant systemic pathology. BioCrystal patents offer diagnostic and therapeutic regimens that address the means to control tumor biology, including system pathology that can be applied in cancer therapy to avoid tumor recurrence and metastasis. More... |
| |
BioCrystal is presently outsourcing portions of its cancer platform technology for third party validation. Currently in progress, or for consideration:
- Immune Corrective Therapy
- ICS – Immune Corrective Surgery
- A Diagnostic/Prognostic Outpatient Test
- Polynucleotides for Inhibition of Tumor Cell Growth and Metastasis
|
|
|
| |
|
Thermo Fisher Scientific Acquires OptiCell ® Product Line
Thermo Fisher Scientific Inc. the world leader in serving science, acquired all assets of the OptiCell Business Unit from BioCrystal Ltd. Of Westerville, OH. More…
|
|
